Which CGRP monoclonal antibody is used for migraine prevention or cluster headache prophylaxis as listed?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which CGRP monoclonal antibody is used for migraine prevention or cluster headache prophylaxis as listed?

Galcanezumab is a CGRP-targeting monoclonal antibody used for prevention. It binds the CGRP ligand, blocking its ability to activate the CGRP receptor, which reduces migraine attack frequency and provides prophylaxis for episodic cluster headaches. It’s given by monthly injections, fitting the preventive role rather than acute treatment. The other options are not monoclonal antibodies: rimegepant and atogepant are small-molecule gepants that block CGRP signaling; sumatriptan is a serotonin receptor agonist used for acute treatment, not prevention. That combination makes galcanezumab the correct choice for migraine prevention and cluster headache prophylaxis.

Galcanezumab is a CGRP-targeting monoclonal antibody used for prevention. It binds the CGRP ligand, blocking its ability to activate the CGRP receptor, which reduces migraine attack frequency and provides prophylaxis for episodic cluster headaches. It’s given by monthly injections, fitting the preventive role rather than acute treatment.

The other options are not monoclonal antibodies: rimegepant and atogepant are small-molecule gepants that block CGRP signaling; sumatriptan is a serotonin receptor agonist used for acute treatment, not prevention. That combination makes galcanezumab the correct choice for migraine prevention and cluster headache prophylaxis.

More practice questions